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Abstract   
 
Background:  Osteoarthritis is the most common joint disorder in the world today and 
affects over 27 million individuals in the US. The standard treatment of osteoarthritis is 
the use of NSAIDs, which come with a list of potentially serious side effects, the most 
common being GI perforation and bleeding. Bromelain, a proteolytic enzyme that is 
found in the stem of the pineapple plant may be an effective alternative to typical NSAID 
therapy with a lower risk profile. Bromelain is currently sold as a combination with other 
enzymes such as rutin and trypsin. The purpose of this review is to evaluate the efficacy 
of oral enzyme combinations to the potent NSAID diclofenac in the management of 
osteoarthritis.  
Method:  An extensive literature search was done using CINHAL, Medline, Evidence-
Based Medicine Reviews Multifile, and Web of Science. The search included the terms 
Bromelain, Arthritis and Non-Steroidal Anti-inflammatory agents.  
Results:  Five randomized control trials met the inclusion criteria. Each study was very 
similar with respect to study design and results. Primary outcomes were pain and function 
measured most often with the Lequesne Index, the VAS or a variation of the two. Each of 
the 5 studies showed that the oral enzyme combination was as effective as diclofenac in 
the treatment of osteoarthritis with regards to the primary outcome. 
Conclusion: This review showed that Oral enzyme therapy is as effective as diclofenac 
in the treatment of osteoarthritis and can be recommended to patients because of its 
efficacy and low risk-to-benefit ratio. 
 
Keywords: Bromelain, Arthritis, and Non-Steroidal Anti-inflammatory agents 
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Efficacy of Oral Enzyme Combination vs. Diclofenac in the 
Management of Large Joint Osteoarthritis: A Systematic Review   
 
BACKGROUND 
Osteoarthritis (OA) is the most common joint disorder in the world and is one of 
the most frequent causes of pain and loss of function in adults. Radiologic evidence of 
OA occurs in most people by age 65 and in 80% of those 75 and older. In the US it is the 
second most common cause of work disability in men over 50 years of age.1 The Rate of 
OA in the US has increased from 21 million in 1995 to over 27 million in 2008. 2,3   
 Standard treatment of OA is the use of a class of medications called non-steroidal 
anti-inflammatory drugs, also known as NSAIDs. NSAIDs are symptom modifying drugs 
and do not modify the disease itself. However, the prolonged use of NSAIDs is often 
associated with the increased risk of gastric and duodenal ulcers and upper 
gastrointestinal perforation and bleeding.4 There is also a risk of acute renal failure as 
well as an increase in cardiac risk, such as heart attack or stroke, associated with long 
term and high dose use of NSAIDs. 
 Bromelain, a proteolytic enzyme derived from the stem of the pineapple plant, 
may be an effective alternative to NSAIDs as the standard of care in the treatment of OA. 
Bromelain is found most commonly in combination with other enzymes. PhlogenzymTM 
contains 90mg bromelain, 48mg trypsin and 100mg rutin. WobenzymeTM contains 45mg 
bromelain, papain, trypsin, chymotrypsin, pancreatin, lipase and amylase.  Proteolytic 
enzymes such as trypsin and bromelain have shown in vivo and in vitro to have anti-
inflammatory, anti-edematous, antithrombotic and fibrinolytic effects.5 Enzymes have 
been shown to be much better tolerated when compared to NSAIDS and do not have the 
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same gastrointestinal effects.6 These oral enzymes have also proven to be non-toxic, 
mutagenic or tetratogenic in previous animal studies.7,8  
 Diclofenac sodium is a prescription strength NSAID and is among the more 
potent NSAIDs used in acute and chronic pain. Diclofenac is also one of the most 
commonly prescribed NSAIDs in the treatment of OA. As compared to ketorolac, 
diclofenac is shown to have a better tolerance profile and lower risk of gastrointestinal 
effects such as bleeding peptic ulcers.9  
 Because of the high prevalence of OA and the risks associated with the standard 
use of NSAIDs, it is important to consider alternative treatments. The objective of this 
review is to evaluate the efficacy of oral enzyme combination in the management of large 
joint osteoarthritis as compared to traditional NSAIDs, in this case diclofenac.  
 
METHODS 
Search Strategy  
 An extensive literature search was done using the following databases accessed 
through Pacific University Library: CINHAL, Medline, Evidence-Based Medicine 
Reviews Multifile (EBMRM), and Web of Science (WOS). The search included the 
following search terms: Bromelain, Arthritis, and Non-Steroidal Anti-inflammatory 
agents. These terms were used individually and in combination. These articles were then 
screened by reviewing the titles and abstracts. The articles were then reviewed for quality 
and validity using the Grading of Recommendations Assessment, Development and 
Evaluation (GRADE) scale. (See table I.) 
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RESULTS 
A comprehensive literature search of four databases using the specified search 
strategy, resulted in 78 total articles of which 5 met the inclusion criteria and were 
relevant to the clinical question of, the efficacy of oral enzyme therapy as compared to 
NSAIDs in the treatment of osteoarthritis. All five articles included in this review were 
double-blinded randomized control trials comparing PhlogenzmTM to diclofenac. (See 
Table I.)  
Klein et al 2000    
In 2000, Klein et al10 preformed a randomized, double-blinded prospective study 
to address the short-term efficacy of an oral enzyme preparation compared to Diclofenac 
in patients suffering from painful osteoarthritis of the knee. The trial included 73 patients, 
who were randomized to receive 3 weeks of the oral-enzyme Phlogenzym, which 
contains bromelain, trypsin, and rutin, or the NSAID diclofenac. Patients were eligible 
for the study if they presented with symptomatic gonarthritis and radiological evidence of 
joint space narrowing and a Lequesne index score (LI), which measures pain and 
function, of ≥ 10 at baseline. (See appendix A.) Exclusion criteria included other anti-
rheumatic treatment within 2 weeks of the study, pregnancy or lactation, oral 
anticoagulants, systemic or intra-articular corticosteroids within 2 months of study, and 
cardiovascular, gastrointestinal, hepatic, hematological or renal diseases. No other 
treatment was allowed during the 3 weeks of this trial.10  
The 73 enrollees were randomized to two groups, Diclofenac (n=37) or 
Phlogenzym (n=36). The double-dummy method was used by giving placebo tablets to 
each group in the dose regimen of the other.10  
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Efficacy was evaluated primarily using the Lequesne index at baseline, 3 weeks 
and at 7 weeks without breaking code. The visual analogue scale (VAS) was also used to 
document pain at rest, pain on movement, and restricted movement. The mean score of 
the LI for the enzyme group decreased from 13.56 at baseline to 3.10 at the end of 3 
weeks to 2.05 at the end of 7 weeks from baseline. The mean score of the LI for the 
diclofenac group decreased from 14.04 at baseline to 3.50 at 3 weeks to 2.24 at the end of 
7 weeks. The lower bound of the 95% CI of the Mann-Whitney estimator was at all 
intervals above 0.44 which is the limit for equivalence. In the enzyme group the VAS 
sum score of pain was markedly reduced after 1 week of treatment (mean sum score 16.9 
at baseline to 6.93, a 59% improvement from baseline) and continued to decrease to 2.12 
after 3 weeks and to 1.01 at 7 weeks. Similar results were noted in the diclofenac group: 
mean sum score 17.42 at baseline decreased to 60.2% at week 1 (numerical mean sum 
score at week 1 was not included in text or in the table, only percentage was given in 
text), 2.24 at week 3 and 0.99 at week 7. Only one patient from the enzyme group 
withdrew because of adverse effects, a headache that was “probably not drug related.” 
There were 3 patients who withdrew from the diclofenac group due to adverse effects, 
sinus bradycardia, which was likely not drug related, duodenal ulcer and nausea, which 
were possibly drug related. 10   
 
Klein et al 2006   
 In 2006, Klein et al11 put out a study addressing the efficacy of an oral enzyme vs. 
diclofenac in the management of osteoarthritis (OA) of the hip. The study was a 
randomized, double-blinded, parallel group trial, which lasted for 6 weeks of treatment. A 
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total of ninety patients were included in this study and randomized into two groups, one 
group to receive the oral enzyme Phlogenzym (n=45) and the other to receive diclofenac 
(n=45). Inclusion criteria for the study were: patients over 20 years of age, radiological or 
CT evidence of OA, WOMAC visual rating scale (VRS) subscale pain >= 20 out of a 
possible 50, Lequesne Index of >= 10. Excluded from the study were patients with a 
current medical or arthritic disease or abnormal laboratory results that could potentially 
confound the results. Also excluded were patients who received steroid or hyaluronic 
acid injections within 2 months of the study or systemic steroids within 4 weeks of the 
study. The enzyme group received Phlogenzym three times a day (t.i.d.), diclofenac was 
administered twice a day (b.i.d.), and each group also received a placebo following the 
double dummy technique.11  
 Primary efficacy was measured using the Lequesne index and the WOMAC index 
(Western Ontario McMasters Osteoarthritis index). A total of 88 subjects were part of the 
intent-to-treat analysis (ITT), 72 patients were analyzed for per protocol. The WOMAC 
total index at baseline was between 68 and 194 and was 121.6+- 22.5 on average +- SD. 
The Lequesne index varied between 10.0 and 14.0 and baseline and was 11.44 +- 1.24 on 
average +- SD. In the ITT analysis, non-inferiority of the oral enzyme was shown as 
compared to diclofenac with regard to the O’Brien Global sum from baseline to endpoint 
in the 4 primary endpoints of pain, stiffness, function and Lequesne index, with a p-value 
of 0.0025. Individual p-values were given for each of the individual scales: WOMAC 
pain (p=0.0033), WOMAC stiffness (p=0.0061), WOMAC function (p=0.0039) and 
Lequesne index (p=0.0008). The per protocol analysis set showed an even clearer 
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tendency in favor of oral enzymes with a treatment difference of 1.05+-0.79 and a 95% 
confidence limit of -2.63/0.53. 
A total of 46 patients, 23 in each group, had at least one adverse side effect. In the 
enzyme group 11 (24.4%) were classified as “possibly drug related.” In the diclofenac 
group 13 (28.9%) were “possibly drug related.” GI disorders were the most common 
adverse events. Dropout was 6/45 (13.3%) in the DC group and 5/45 (11.1%) in the 
enzyme group. 11    
Akhtar et al   
 In 2004, Akhtar et al12  published a double blind, prospective, randomized study 
on oral enzyme combination vs. diclofenac in the treatment of osteoarthritis of the knee. 
The study included a total of 103 patients that were treated for a total of 6 weeks at two 
study centers. The main inclusion criteria were symptomatic OA of the knee confirmed 
by radiology and LI of >= 10. Patients were excluded if they had been treated for OA 
within 2 weeks of baseline, had rheumatoid arthritis or had received systemic or intra-
articular steroids within 2 months of baseline. Patient evaluations were done at baseline, 
2, 4, and 6 weeks. Primary efficacy criteria were the Lequesne index and complaint 
index, which includes pain at rest, pain with movement and restricted function. Each of 
the 3 domains was rated on a visual analog scale (VAS) ranging from 0 (best) to 10 
(worst) with a total possible score of 30.12  
 The ITT population included 98 patients (enzyme 46/diclofenac 52). A total of 56 
patients (enzyme 24/diclofenac 32) were evaluated in the per protocol population. A total 
of 20 patients  (10 in each group) discontinued the study early. In the ITT population the 
mean LI decreased from 13.0 to 9.4 (26.3%) in the enzyme group, and from 12.5 to 9.4 
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(23.6%) in the diclofenac group. Non-inferiority was measured using the Mann-Whitney 
estimator. The analysis was performed as one-sided sets with 97.5% CIs. Non-inferiority 
was considered to be proven if the lower bound of the CI was greater than MW=0.36. 
Non-inferiority of the oral enzyme in the ITT population was demonstrated 
(MW=0.5305; CI-LB=0.4171) at 6 weeks. Also at 6 weeks, the mean complaint index 
from the sum of all three domains, decrease from 4.9 to 3.5 (30.2%) in the enzyme group 
and from 4.9 to 3.6 (26.6%) in the diclofenac group. Again non-inferiority of the oral 
enzyme was demonstrated (MW=0.5434; CI-LB=0.4296). 12   
Singer et al   
In 2001, Singer et al6  published a double-blind randomized study that compared 
the efficacy of PhlogenzmTM to diclofenac in the treatment of OA of the knee. Patients 
were included in the study if they had symptomatic OA with evidence of joint space 
narrowing on radiography as well as a LI of >= 10. This study included 63 patients 
randomized to two groups, oral enzyme (OE) n=31 and DC n=32. The double dummy 
technique was applied in this study. The study duration was 3 weeks with a follow up at 7 
weeks from baseline. Examinations were made at weeks 1, 2, 3 and 7. Efficacy was 
measured using the LI and the VAS and all patients were evaluated in the intent-to-treat 
analysis. In the enzyme group using the LI, 29/31 patients showed improvement and 2-
showed deterioration. In the diclofenac group using the LI, 28/32 showed improvements, 
one showed no change and 3-showed deterioration. The mean value of the LI decreased 
from 15.48 to 9.81 in the OE group after 7 weeks. The mean value of the LI decreased 
from 15.81 to 10.83 after 7 weeks in the DC group. In the statistical evaluation, the lower 
band 95% CI of the Mann-Whitney estimator was above 0.44 at all times which is the 
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limit for equivalence. The reported tolerance for the enzyme group was 18 AE in 15 
patients, which included flatulence, nausea, allergic exanthema and epigastric pain. In the 
DC group 20 AE were reported in 16 patients, which included retrosternal pain, pressure 
and pain over stomach, epigastric pain, nausea and ulcus ventriculi. 6    
Tilwe et al   
 In 2001, Tilwe et al13  published a single-blinded randomized open trial 
comparing the efficacy of PhlogenzymTM to diclofenac in the treatment of osteoarthritis 
of the knee. Patients were included if they had active arthritis of the knee and radiologic 
evidence of joint space narrowing. Patients were excluded from the study if they had 
recently received anti-rheumatic therapy, suspected bacterial infection of the knee joint, 
existing pregnancy or lactation.  A total of 50 patients were included in the study, 25 
were randomized to each group. Patients in the study group received 3 tablets of 
Phlogenzym b.i.d. for the first week and then 2 tablets b.i.d. for the second week. Patients 
in the control group received 50mg diclofenac b.i.d. for all three weeks of the study. 
Patients were examined at baseline, 3 weeks (end of study), and at 7 weeks from baseline, 
by evaluators who were different from those dispensing the medication. Pain was 
subjectively assessed by rating pain at rest or on movement as none, mild, moderate or 
severe and improvement was noted as severe to moderate, moderate to mild and so on. 
Joint tenderness was also assessed in a similar fashion.13  
 Eighteen patients in the oral enzyme (OE) group vs. 10 in the diclofenac group 
had reduction in joint tenderness at the end of the study (p=0.05). In the OE group 12 
showed reduction in pain at rest and 17 showed reduction in pain on movement as 
compared to 9 and 15 in the diclofenac group, respectively. Neither group suffered 
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dropout or loss to follow up.  Statistical analysis showed no significant difference in 
efficacy between the two groups.13  
 
DISCUSSION 
 It is known that osteoarthritis has a high prevalence across the US and the world 
and physicians are continuing to reach to NSAIDs as first line symptom control for these 
patients. As previously mentioned NSAIDs do not come without risk, GI risk being the 
most common.4 Wouldn’t it be beneficial if there were a drug that could reduce pain and 
improve mobility as effectively as NSAIDs without the associated risks?  
Although oral enzyme therapy has proven to be better tolerated and have fewer 
AE as compared to NSAIDs9 and although some of the studies in this review make 
mention of the tolerance and AE of the oral enzyme, that was not the outcome to be 
considered in this review. The purpose of this review was only to show the effectiveness 
of OE therapy when compared to NSAIDs. Studies addressing the long term AE of oral 
enzyme therapy should be investigated to more accurately address tolerance and risk.   
This systematic review, which included 5 studies addressing the effectiveness of 
oral enzyme therapy compared to diclofenac in the management of large joint 
osteoarthritis, shows that PhlognezymTM is as effective as diclofenac in the treatment of 
osteoarthritis. 
All 5 studies included in this review were very similar in study design and results 
were consistent across all studies in regards to diclofenac vs. oral enzymes. (Tables I & 
II) However, there were found to be some variation and limitations among them that 
should be noted. 
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Four of the 5 studies6,10,11,12 were double-blinded randomized control trials (RCT) 
that used a double-dummy technique in the administration of the medications. The Tilwe 
et al13 study was an open randomized single-blinded study and did not use the double-
dummy technique in the administration of the medications. All 5 studies used the same 
study drug and the same drug for control, which is an important consistency among the 
studies.  
Three of the five studies6,11,12 followed the intention-to-treat (ITT) analysis (table 
2). The Klein et al11 2006 study was the only study to use the ANCOVA (analysis of co-
variants) as part of their statistical methods. Prognostic balance between the study group 
and the control group was not shown in the Klein et al10  2000 study. This could have an 
impact on results if the groups were not similar at the start and end of the study. Each 
study however, was similar with respect to the inclusion and exclusion criteria of the 
patients.   
 Patient important outcomes that should be considered are, pain, function, 
activities of daily living, and AE. The Lequesne index accounts for the first three of these 
outcomes. Three of the 5 studies6,10,12 used the Lequesne index (LI) exclusively as their 
measure of the primary outcome. The Lequesne index is a questionnaire that includes 
three categories: Pain and discomfort, Maximum distance walked, and Activities of daily 
living. Each category can score a potential 8 points for a total potential score of 24. (See 
Appendix A.) Outcomes were also measured using the visual analog scale (VAS), 
sometimes referred to as the complaint index, which rated pain at rest, pain with 
movement, and restricted function. Each category was rated on a scale of 0-10 for a total 
potential score of 30. The Klein et al11  2006 study used the Lequesne index along with a 
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similar scale called the WOMAC, which evaluated pain, joint stiffness, and function. It 
did not report the mean LI as a numerical value but as a p-value only (p=0.0008) making 
comparison all but impossible. The Tilwe et al13  study did not use the Lequesne index or 
the VAS but used a much more subjective 4 point rating scale, measuring pain at rest and 
pain with movement with the patient rating each as none, slight, moderate or severe. It is 
unclear how points were assigned to this scale, whether or not it was a 0-3 scale or a 1-4 
scale. The subjective nature of this measurement is concerning because of the potential 
for bias which affects the validity of the results.  
All 5 studies included in this review had very small sample sizes, the largest being 
103 total patients (table 2). This was one of the reasons of a downgrade on the GRADE 
scale. Only one study (Singer et al) did not recognize the role Mucos Pharma or Pacific 
Pharmaceutical in the study. This presents possible bias within the studies, which could 
have an impact on the validity of the results. Another questionable area is the author’s 
assessment of which AE were drug related, not drug related or “possibly drug related” 
with no apparent attempt to explain these classifications. In the studies which reported 
AE6,10,11,12 it was not stated whether or not the investigators reporting the side effects 
were blinded also, adding in potential bias if they were in fact not blinded. While some of 
the outcomes were not of primary interest in this review, the fact that bias could well be 
an issue has implications for the studies as a whole beyond the specific outcomes because 
bias anywhere in a study suggests bias everywhere.  
The similarities mentioned across studies helps support the validity of their result 
and helps make the overall conclusion that oral the enzyme combination is as effective as 
diclofenac in the treatment of OA. Based on the overall grade of these studies, which is 
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moderate, further research is likely to have improve our confidence in the effect and may 
change the effect. A larger sample size and a multicenter approach would yield greater 
precision. Allocation concealment and further steps in blinding would also increase the 
validity of such a study and support the clinical application of oral enzyme therapy.  
 
CONCLUSION 
In conclusion, the main focus of this review was on the efficacy of oral enzyme 
therapy as compared to diclofenac. Primary outcomes were in large part measured using 
either the Lequesne index or the VAS, or some sort of variation of the two. These 
measurements mainly focused on the pain and function of the patient. The efficacy of the 
oral enzyme was shown to be statistically equivalent to diclofenac in all outcomes 
measured across all 5 studies. Although the over all grade of the studies was moderate, 
which means further studies would likely be of benefit in our confidence of the effect but 
not is not likely to change the effect, a recommendation could be made to use oral 
enzyme therapy in patients suffering from OA. This recommendation would be justified 
because of the nature of the oral enzyme and its low risk to benefit ratio. This therapy 
could be especially beneficial in patients that may already be suffering from AE from 
NSAIDs or that can no longer take NSAIDs due to AE.  
Other patient important outcomes that would be of benefit to know would be 
addressed by long-term studies that show whether or not there is a delay in time to hip or 
knee replacement with the use of OE therapy. A long-term study looking at the harm of 
diclofenac vs OE would also be of benefit, showing what the harm would be of not using 
OE.
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Table I. Characteristics of Reviewed Studies 
 
 Study 
 
 
Design Findings Starting 
Grade 
Decrease Grade Grade of 
Evidence  
Overall 
Grade Of 
Evidence 
Li
m
ita
tio
ns
  
In
co
ns
is
te
nc
ie
s  
In
di
re
ct
ne
ss
 
Im
pr
ec
is
io
n 
 
Pu
bl
ic
at
io
n 
B
ia
s 
Akhtar et al12 
RCT No inferiority High 0 0 0 -1c 0 Moderate   
 
 
 
Moderate  
Klein et al10 
2000 
RCT No inferiority High -1a 0 0 -1c 0 Low  
Singer et al6 RCT No inferiority High 0 0 0 -1c 0 Moderate  
Klein et al11 
        2006  
RCT No inferiority High 0 0 0 -1c 0 Moderate 
Tilwe et al13 RCT  No inferiority  High -1b 0 0 -1c 0 Low 
a failure to report prognostic balance  
b no use of double-dummy technique  
c small sample size   
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Table II. Summary of Findings 
 
Study Length 
of 
study 
in 
weeks 
Dosing schedule Lequesne Index (LI) 
(Mean) 
VAS WOMAC Mann-Whitney ITT 
Analysis 
OE DC OE DC OE DC OE DC OE 
Akhtar 
et al12 
6  tid 50mg 
bid 
13.0 to 
9.4 
12.5 to 
9.4  
4.9 to 
3.5  
4.9 to 
3.6 
NA 0.5305 Yes 
Klein 
et al10 
(2000) 
3 2 tabs 
tid 
50mg 
tid wk 
1 then 
50mg 
bid 
13.56 to 
3.10  
14.04 to 
3.50  
16.90 
to 2.12 
@ 3 
weeks 
17.42 
to 2.24  
NA 0.5462 No 
Singer 
et al6 
3 2 tabs 
tid 
50mg 
tid wk 
1 then 
50mg 
bid 
15.48 to 
10.97 
15.81 to 
10.83 
12.37 
to 5.51  
11.05 
to 5.36  
NA 0.4919 Yes 
Klein 
et al11 
(2006) 
6 2 tabs 
tid 
50mg 
bid 
P=0.0008  NA   P=0.0025  No Yes 
Tilwe 
et al13 
3 3 tabs 
bid 
50mg 
bid 
NA NA  NA No 
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APPENDIX A  
Lequesne Index14  
I. Pain or discomfort  
Parameter  Finding  Points  
Pain or discomfort during 
nocturnal bedrest  
None  0 
 Only on movement or in certain 
positions  
1 
 Without movement  2 
Duration of morning stiffness 
or pain after getting up 
None  0 
 Less than 15 min 1 
 > = 15 min 2 
Remaining standing for 30 
minutes increases pain 
No  0 
 Yes 1 
Pain on walking  None 0 
 Only after walking some 
distance  
1 
 Early after standing  2 
Pain or discomfort in sitting 
position for 2 hours  
No  0 
 Yes  1 
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II. Maximum distance walked  
Parameter  Finding Points 
Maximum Distance Walked  Unlimited  0 
 > 1 kilometer but limited  1 
 About 1 kilometer (about 15 
minutes) 
2 
 About 500-900 meters (about 8-
15 minutes) 
3 
 From 300-500 meters 4 
 From 100-300 meters 5 
 < 100 meters  6 
Waking aid required  None  0 
 1 walking stick or crutch  1 
 2 waking sticks or crutches  2 
 
III. Activities of daily living  
Parameter  Finding Points  
Can you put on socks by 
bending forward?  
Easily  0 
 With mild difficulty  0.5 
 With moderate difficulty  1 
 With marked difficulty  1.5 
 Impossible  2 
Can you pick up an object 
from the floor? 
Easily  0 
 With mild difficulty  0.5 
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 With moderate difficulty  1 
 With marked difficulty  1.5 
 Impossible  2 
Can you go up and down a 
flight of stairs? 
Easily  0 
 With mild difficulty  0.5 
 With moderate difficulty  1 
 With marked difficulty  1.5 
 Impossible  2 
Can you get into and out of a 
car? 
Easily  0 
 With mild difficulty  0.5 
 With moderate difficulty  1 
 With marked difficulty  1.5 
 Impossible  2 
 
Lequesne Index of severity  
INDEX SCORE  HANDICAP 
0 None  
1-4 Mild  
5-7 Moderate  
8-10 Severe  
11-13 Very Severe  
>= 14 Extremely Severe  
 
